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ABSTRACT
Natural killer (NK) cells are large, granular, and cytotoxic innate
lymphocytes which do not require prior antigenic exposure to target cancerous and
virally infected cells. NK cells possess activating and inhibitory receptors which
may activate or inhibit NK cell activity, respectively.

In mice, the inhibitory

NKR-P1B receptor on NK cells recognizes the C-type lectin-related protein-b (Clrb) ligand expressed on most autologous cells but downregulated on many tumour
cell lines. In B cell lymphoma models, the disruption of NKR-P1B:Clr-b
interaction results in delayed tumour development and progression, suggesting that
blockage of inhibitory signals from NKR-P1B augments NK cell activity against
lymphoma cells. The goal of our research is to evaluate the role of NKR-P1B:Clr-b
interaction in a solid tumour model, namely, breast cancer. We used a E0771 cellinduced mammary tumour model to evaluate mammary tumour growth, and the
activity of tumour-infiltrating NK cells in NKR-P1B-deficient and WT mice.
When we compared tumour onset and development of Nkr1b-/- (KO) versus
Nkrp1b+/+ (WT) MMTV-PyVT mice, we found that the knockout mice develop
tumours earlier than their wildtype counterparts. We also found that the
phenotypes of tumour-infiltrating lymphocytes of WT vs. KO MMTV-PyVT mice
differed. When we looked at infiltration of Clr-b-expressing myeloid-derived
suppressor cell (MDSC) into these tumours, we found that infiltration of MDSCs
into tumours of Nkrp1b-/- mice is greater than WT mice. These findings in mice are
significant because they reveal the role of NKR-P1B:Clr-b interactions in NK cellmediated immunosurveillance of mammary tumours.
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CHAPTER 1: INTRODUCTION
1. Natural killer cells
Natural killer (NK) cells are innate effector lymphocytes which belong to group 1
innate lymphoid cells (ILC1). They are involved in early defense against transformed and
virus-infected cells, without prior sensitization. As patrols and frontline fighters, they are
strategically located throughout nonlymphoid and lymphoid tissues, alike, in order to
quickly detect and eliminate intruders and transformed autologous cells. As such, NK
cells represent 5-20% of circulating lymphocytes in humans and 2-5% in spleens and
bone marrow (BM) of mice 1,2. The goal of NK cells is to survey the immune system and
to detect and destroy defectors and intruders.
1.1. The discovery of natural killer cells
In the early 1970s, studies of T-cell immune reactivity to tumour antigens in cancer
patients and animal models by various groups led to the appearance of non-specific
reactivity in vitro. Prior to the findings in the early 1970s, it was unthinkable that
lymphocytes could possibly be responsive against tumour cells without prior
sensitization. In 1966, however, H.J. Smith from the University of Leeds, School of
Medicine published an article regarding the antigenicity of spontaneous tumours in mice
where he implied the possibility of innate host resistance to spontaneous tumour
transplants 3. These observations paved the way into the realm of innate cell cytotoxicity
and the later discovery of NK cells. Eugene B. Rosenberg, Ronald B. Herberman, and
their associates reported observing subsets of innate immune cells which exhibited
natural cytotoxic reactivity when looking into reactivity to leukemia-associated antigens
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by lymphocytes. They hypothesized the existence of tumour surveillance mechanisms to
explain the ability of lymphocytes from normal individuals to lyse tumour antigenbearing cells 4. Herberman and associates published their findings in 1975 which shed
some light on the phenotypes of natural cytotoxic “N-cell” in mice against a variety of
syngeneic and allogeneic tumour lines. They were able to rule B- and T- cells out as the
cause of cytotoxicity against tumour lines since they could not detect their cell surface
markers on the effector cells and concluded that these were a completely distinctive
subpopulation of lymphoid cells

5,6

. The same year Rolf Kiessling, at the Karolinska

Institute in Stockholm, described similar findings of naturally cytotoxic cells against
mouse Moloney leukemia cells, which are infected with the oncogenic murine leukemia
virus (MLV). They designated these cells “natural killer” cells based on their nonspecific cytotoxicity

7,8

. At the very early stages of NK cell research, NK cells were

identified not by the markers we now recognize (ex. NK1.1, NKp46, DX5 in mice, and
CD56 in humans), but by their lack of typical lymphocyte (B and T) markers

5,9

. Later

that decade, a group at the University of Helsinki isolated and characterized human NK
cells through adsorption-elution of the effector cells from K562 target cells, a
myelogenous leukemia cell line. They observed that these lymphocytes were large with a
pale cytoplasm filled with granules

10,11

. Now that these cells were identifiable,

researchers were able to discover unique surface antigens on these large granular
lymphocytes.
1.2. NK cell markers
When NK cells were first discovered, they were initially characterized and described
based on their function and morphology

6,11

. It wasn’t until about a few years later that
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NK cell markers began to be investigated by several groups which investigated a couple
of monoclonal antibodies (mAb) directed against large granular lymphocyte (LGL)
antigens. The first NK cell antigen discovered was CD16 (FcγRIIIa), which is a receptor
for immunoglobulin G (IgG), which, upon binding, activate antibody-dependent cellmediated cytotoxicity (ADCC) activity of NK cells, leading to the killing of the target
cells coated with IgG

12,13

. NK cells can also be distinguished based on the cell surface

concentration of CD56 expression. CD56, also known as NCAM (neural cell adhesion
molecule), and it mediates homophilic adhesion and it binds fibroblast growth factor 1
(FGFR1)14. There are two major subsets of CD56-expressing NK cells: CD56dim and
CD56bright cells. The majority (90%) of NK cells in blood are CD56dim 12. CD56bright NK
cells are dominant in secondary lymphoid tissue (SLT) while CD56dim cells can be
predominantly found in BM, blood, and spleen. CD56bright NK cells express c-kit (or
CD117, the receptor for stem cell factor), IL-2Rɑ (CD25). CD56dim NK cells express IL2Rβ (CD122) and IL-2Rγ (CD132)

15

. In the late 1980s, it was postulated that the

CD56dim NK cells were more mature than their bright counterparts since they displayed a
higher cytotoxic capacity against tumour cells12. Some other human NK cell markers
include cell surface inhibitory receptors such as NKG2A and activating receptors such as
NKG2D and NKp46. Human NK cells do not express CD3, which is a protein complex
associated with the T cell receptor (TCR) and contribute to activation of both CD8+
(cytotoxic) and CD4+ (helper) T cells 16,17.
In C57BL/6 mice, NK cells were first characterized by the murine NK cell antigen,
NK1.1 (CD161) 18. They do not express CD3 or TCR. Murine NK cells express CD11b
(integrin alpha M) and CD27. NK cells that are CD11b+CD27+ are mature and highly
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cytotoxic19. DX5 (CD49b, integrin alpha 2) is also a marker expressed by NK cells and
natural killer (NKT) T cells in addition to NK1.1 20. Mouse NK cells also express a wide
array of activating and inhibitory receptors which control their functions. Inhibitory
receptors include Ly49 and NKR-P1B, while some activating receptors include NKp46
and NKG2D 21.
1.3. NK cell development
Murine BM niches are the site of NK cell development and house hematopoietic stem
cells (HSCs) which are multipotent and self-renewing. HSCs are characterized by a lack
of lineage markers, and the expression of c-kit and Sca2 (Lin-c-kit+Sca2+) 22. HSCs give
rise to all red and white blood cells and more specifically, the oligopotent common
lymphoid progenitor (CLP). The CLP gives rise to Pro-B, CD122+ Pre-T/NK precursors
(NKPs). These cells are identified as Lin-IL-7R+Thy-1-Sca-1loc-kitlo and they are capable
of reconstituting B and T lymphocytes, which are antigen-specific, and NK cells, which
lack antigen specificity 22,23. The acquisition of the expression of IL-7Rɑ (CD127), CD27,
and CD244 (2B4) is the earliest committment step from CLPs to cells of the lymphoid
lineage. Expression of IL-15Rβ (CD122) marks the transition from pre-NKPs to NKPs,
which can no longer differentiate into B or T cells
(CD132) -deficient mice lack circulating NK cells

24,25

. IL-15, IL-15Rβ, and IL-15Rɑ

26–28

. IL-15 is presented by dendritic

cells in the developmental niche and they recognize IFN type I signals which, in turn,
results in an upregulation of IL-15 and IL-15Rɑ

29

. Next, NKPs begin expressing high

levels of NK1.1 (NKR-P1C), NKG2C(CD159c)/CD94, and NKG2A (CD159a) and low
levels of CD49b (DX5), CD11b (Mac-1), and CD43 (leukosialin)

30,31

. Afterwards,

immature NK cells (iNK) move into the mature NK cell (mNK) stages whereby there is
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an acquisition of Ly49 receptors

32

. Finally, NK cells have reached terminal maturation

when they downregulate CD27 and express CD11b and killer cell lectin-like receptor G1
(KLRG1), an inhibitory receptor

33

. At full maturity, NK cells acquire cytotoxicity and

cytokine production 32.
1.4. Missing-self hypothesis and NK cell education
In 1981, a study revealed that as target cells mature to acquire MHC expression, their
susceptibility to NK cell-mediated lysis is lost 34. From this phenomenon, the “missingself” hypothesis was postulated. In essence, NK cells are able to recognize the absence of
certain molecules which are constitutlvely expressed on normal cells, and mount a
“missing-self” response in which these target cells are destroyed

35–37

. Kärre et al.

confirmed this phenomenon by using two different lymphoma cell lines, derived through
mutagenesis, which differentially express the class I major histocompatability complex
(MHC-I): RMA cells did express MHC-I and RMA-S did not. When the two cell lines
were injected in a syngenic host, they observed that RMA cells survived injection while
RMA-S cell did not. In vitro experiments showed that RMA-S cells are killed efficiently
by NK cells, which implied that NK cells are able to recognize the loss of MHC-I
expression in RMA-S cells and when NK cells are depleted from the mice, RMA-S
survived

38,39

. Basically, NK cells were recognizing and destroying cells lacking MHC-I

molecules on their surface. This phenomenon seen in mice is also observed in humans
because human NK cells also recognize and destroy cells which have decreased
expression of MHC-I

40

. It is also possible for tumours to engage in immunoediting,

whereby they deceptively upregulate the expression of MHC-I to evade attack by NK
cells but they can also downregulate MHC-I expression to evade CD8+ T lymphocyte
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attack

41,42

. Therefore, NK cells “missing-self” immunosurveillance prevents self-

reactivity and exerts pressure on abnormality and developing tumours, which can result
in the elimination of the tumour or cancer immunoediting.
The most studied NK cell receptor for the MHC-I ligand is the receptor Ly49, in
mice, and killer immunoglobulin-like receptors (KIRs), in humans. Terminal stages of
NK cell maturation is characterized by the acqusition of set of Ly49 receptors, which can
be activating or inhibitory

32

. The MHC-I-Ly49 recognition axis allows for MHC-I-

dependent NK cell education or licensing and the acquisition of effector function

43

.

Mice with Ly49 receptor-deficient NK cells have not been licensed/educated during NK
cell development and cannot reject MHC-I-deficent targets, and therefore have an
impaired missing-self response and are unable to become functionally mature

44

. This

education of NK cells is termed “classincal NK cell education”. There are other ways
through which NK cells become educated involving non-classical MHC-I and MHC-Iindependent methods. For instance, the inhibitory receptor NKG2A/CD94 recognizes the
non-classical MHC-Ib molecules, Qa-1 in mice and HLA-E in humans, and is involved in
NK cell tolerance 45. An example of a non-MHC-I-recognizing NK cell receptor involved
in NK cell education is inhibitory receptor NKR-P1B, which recognizes C-type lectinrelated protein b (Clr-b). The absence of receptor NKR-P1B or its cognate ligand, Clr-b,
has been shown to result in NK cells with diminished responsiveness to Clr-b-deficient
targets and secretion of pro-inflammatory IFN-γ 37,46.
1.5. NK cell function
The two major functions of NK cells are cytotoxicity as well as cytokine and
chemokine production. While they differ in their method of target recognition, NK cells

6

and CD8+ T lymphocytes share many common characteristics and they have
complementary roles in the immune system. Cytotoxic T lymphocytes play a major role
in the adaptive immune response by specifically recognizing antigens bound to MHC-I
through the T-cell receptor and mediating an apoptotic response in the target cell. While
similar in their effector response, NK cells lack antigen specificity but their recognition
of cellular targets is not limited to MHC presentation47,48.
The effector molecules of NK cells include perforin and granzymes. When perforin is
lacking, NK cell-mediated apoptosis induction in target cells is reduced but not
completely eliminated because granzyme activity is still functional and NK cells have
several other ways of killing their targets independ of perforin and granzyme activity

49

.

Perforin and granzymes work synergistically to kill NK cell targets. Granzymes are
serine proteases packaged in cytotoxic granules with perforin, which induce apoptosis in
abnormal or infected cells when NK or cytotoxic T cells form a synapse with targets.
When NK cells release their granules, perforin binds to the target cell’s surface and
polymerizes in a Ca2+-dependent manner to form a pore complex

50–52

. Calcium ions bind

the phosphatidylcholine of cell membranes, which increases the affinity of perforin to the
cell membrane of the target

53

. Granzymes may passively diffuse through the pores

formed by perforin and initiate apoptosis in the target cell. The pores in the cell
membrane also disrupt mineral homeostasis of the target cell since ions and polypeptides
are free to passively diffuse into and out of the cell – this also allows the activation of
pro-apoptotic pathways independently of granzymes53.While perforin release into the
immune synapse allows entry of granzymes into the target cell, granzymes can enter in
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without the activity of perforin 54. NK cells use both granzyme A and B to cause DNA
damage, but only granzyme B induced apoptosis in the target cell 54.
Natural killer cells have several other ways of killing their target cells indepent of
cytotoxic granules to induce apoptosis. NK cells may engage death receptors in the target
cell using the Fas ligand (FasL) and the TNF-related apoptosis-inducing ligand (TRAIL)
to induce cell death in target cells

55

. A third way NK cells kill their targets is through

ADCC, which is a mechanism of immune defense whereby effector cells lyse target cells
after their recognition of antibodies found to membrane surface antigens of target cells.
Immune effector cells express Fc-gamma receptors (FcγR) which recognize cell-bound
antibodies such as IgG. NK cells express the Fc receptor called CD16, which recognizes
cells coated with IgG and the cross-linking of the Fc receptors triggers the activation of
the NK cell to release its cytoxic granules into the immune synapse 56.
Natural killer cells may also be via cytokines in an inflammatory microenvironment
in which they can be induced to produce proinflmmatory cytokines and chemokines, such
as IFN-γ, tumour necrotic factor-α (TNF-α), and interleukin-10 (IL-10), to activate other
immune cells

57–59

. In the immune system, there are no small parts – only small players.

As their name suggests, cytokines are small immunomodulating peptides that play a
major role in cellular communication by binding to a cell surface receptor and altering
intacellular functions through the regulation of genes and transcription factors

60

.

Interleukins (IL) are a category of cytokines so named due to their expression by a broad
range of white blood cells. Host infection with different pathogens induces the production
of unique cytokine profiles, and therefore, various combinations of cytokines regulate
immune functions57. Proinflammatory cytokines, which are involved in the activation,
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development, and proliferation of NK cells, are secreted by macrophages, phagocytes,
and other immune cells include IL-2, IL-12, IL-15, IL-18, and chemokine ligand 5
(CCL5)57,61,62. IFN-γ expression and production is known to be enhanced through the
synergistic activity of IL-12 and IL-1863,64.
Interferons are antiviral and antitumoural cytokines, so termed due to their ability to
“interfere” with viral infection65.

IFN-γ activates expression of certain target genes

through the JAK-STAT pathway. When STAT1 protein is activated, it can bind to a
protein called p48 which can bind to other DNA recognition sequences, thereby
activating their transcription66. Interferon regulatory factor 1 (IRF1) synthesis is induced
by IFN-γ and this factor is essential in the pathway which leads to killing of tumour cells
and intracellular infectious agents.

In additon, IFN-γ increases MHC-II on the cell

surface of antigen presenting cells (APCs) which increases activation of CD4+ T cells 67.
IFN-γ has antiproliferative effects on viral and malignant transformed cells 68.
1.6. NK cell memory
NK cells are known to be innate immune cells due to their ability to target and
destroy foreign pathogens and transformed cells without prior sensitization. While the
phenomenon known as immunological memory is a cardinal feature of adaptive
immunity, there is mounting evidence which shows that NK cells may acquire memory
like B and T cells

69

.

B and T cells have go through four phases upon infection:

expansion, contraction, memory maintenance, and recall

70,71

. NK cell memory-like

responses were first observed in a little over a decade ago in studies involving chemical
haptens and viral antigens as well as murine cytomegalovirus (MCMV)

72,73

. Since then,

the NK cell memory body of literature has been growing as memory-like response, like

9

those of B and T lymphocytes, are being observed over models of various types of viral
and bacterial infections.
In the C57BL/6 (B6) mouse strain infected with MCMV, NK activating receptor,
Ly49H recognizes the viral glycoprotein m157 which is expressed on MCMV-infected
murine cells 74. When NK cells recognize MCMV-infected cells by virtue of Ly49H, they
become activated, proliferate, and expand, peaking at about 7 days post-infection after
which contraction of the population occurs and the majority of these cells, except for a
small population dies via apoptosis

73

. They found that around half of splenic NK cells

from naïve B6 mice expressed Ly49H, but after a week of MCMV infection, more than
80% of the total NK cell population was Ly49H+. When they used a mutant m157
knockout mouse, they found that proliferation of Ly49H+ NK cells was not preferred
over other NK cell subsets

73

. When they adoptively transferred Ly49H + NK cells into

Ly49H-deficient mice to examine the response to MCMV infection, they found that the
donor Ly49H+ NK cells proliferated 100- to 1000-fold, driven by engagement of the
Ly49H-m157 axis. They found that this pool of Ly49H + NK cells persisted in tissues for
many months

73

. The effectiveness of the response of the Ly49H + NK cell pool

continually improved and they were able to expand even after several rounds of adoptive
transfer, which is indicates a recall response

73,75

. A few years following these findings,

another group showed that DNAM-1 (CD266) – the costimulatory molecule - is needed
for the expansion of Ly49H+ NK cells for optimal differentiation during MCMV
infection 76. DNAM-1 is a cell surface adhesion molecule which functions to co-stimulate
NK cells in conjunction with activating receptors to mediate cytotoxicity when it
encounters CD155 and CD112, its ligands. DNAM-1 is downregulated on mNK cells and
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this results in peripheral DNAM-1+ and DNAM-1- cells

77

. Cytokines also play an

important role in NK cell memory following MCMV infection

78

. For example, one

group found that following MCMV infection, the IL-2-STAT4 axis is essential for
proliferation and memory of selected NK cells and IL-18 and IL-33 are required for the
expansion of Ly49H+ educated NK cells

78–81

. Bim, the proapoptotic factor, was found to

be required for NK cell contraction and BNIP3 and BNIP3L, anti-apoptotic
mitochondrial proteins which remove reactive oxygen species (ROS), allow for the
survival of MCMV-educated NK cells 82,83.
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2. NK Cells and Their Receptors
Unlike B and T lymphocytes, NK cells do not rearrange immunoglobulin (Ig) genes
or the TCR from their germline configuration in order to produce a vaste repertoire of
receptors. They recognize their targets by virtue of an array of receptors which survey
host tissues, detect cellular abnormalities, and respond to cellular stress and virallyinfected cells. NK cell receptors mediate immunosurveillance and the missing-self
response. NK cell receptors are generally classified as either activating or inhibitory
receptors.
2.1. Receptor properties and signaling
Inhibitory receptors posess a signalling motif known as an immunoreceptor tyrosinebased inhibitory motif (ITIM), which is defined by the sequence Ile/Val/Leu/Ser-x- Tyrx-x-Leu/Val where x is any amino acid

84

. When the inhibitory receptor and its cognate

ligand interact, the tyrosine residue of the ITIM becomes phosphorylated by enzymes of
the Sarc family protein tyrosine kinases. When phosphorylated the tyrosine residue
becomes a docking site for the intracellular protein tyrosine phosphatases SHP-1 (srchomology region 2 containing protein tyrosine phosphate-1) and SHP-2 (SH2-containing
protein tyrosine phosphate-2) then become localized near the cell membrane. The
recruitment of these phosphatases will inhibit NK cell activitites through the
dephosphorylation of tyrosine residues on othter intracellular signalling molecules 84,85.
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Figure 1: Immunoreceptor tyrosine-based inhibitory motif (ITIM) Inhibition Pathway
The cytoplasmic tail of inhibitory receptors contains an ITIM. The consensus sequence of
ITIMs (Ile/Val/Leu/Ser-x- Tyr-x-x-Leu/Val, where x is any amino acid) is outlined in the
red box. The tyrosine residue becomes phosphorylated by Sarc family protein tyrosine
kinases, which recruits SHP-1/2. The phosphatases inhibit signaling through
dephosphorylation of tyrosine residues on other intracellular signaling molecules.
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Many NK cell activating receptors do not have a signaling motif in their cytoplasmic
tail like inhibitory receptors. Like T and B cell antigen receptors, they use adapter
proteins containing an immunoreceptor tyrosine-based activation motif (ITAM), which is
defined by the sequence Asp/Glu-x-x-Tyr-x-x-Leu/Ile x6-8 Tyr xx Leu/Ile where x is any
amino acid

86

. The three adaptor ITAM-containing adaptor proteins expressed by NK

cells are FcɛRIγ, CD3ζ, and DAP12 84. When NK cell activating receptors interact with
the ligand which they recognize, the ITAM located on adaptor molecules are
phosphorylated by protein tyrosine kinases of the Src family such as Lck and Fyn. The
phosphorylated ITAMs recruit Syk and Zap70, which leads to the recruitment of linker of
activated T cells (LAT) and SH2 domain-containing leukocyte phosphoprotein (SLP-76)
87

. Syk and ZAP10 are not necessary for development of NK cells since mice that are

deficient in both of these still have operational NK cell effector function

88

. DAP10 is

another Syk-independent adaptor molecule expressed by NK cells which triggers
activation of NK cell effector function 87. DAP10 signalling induces phosphatidylinositol
3-kinase (PI3K) signalling which ultimately leads to downstream convergence with
ITAM-containing adaptors which leads to NK cell cytotoxicity

87

. DAP10 signalling

leads to NK cell cytotoxicity but signalling through ITAM-containing adaptor molecules
leads to both NK cell cytotoxicity and cytokine production through phospholipase C-γ1
activation, resulting in Ca2+ influx 84,87.
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NK cell function is determined by a balance of the stimulation of activating and
inhibitory signals. When activating signals prevail, NK cells will release their cytotoxic
granules into the immune synapse to destroy the target cell, and it will produce cytokines
to activate other immune cells in the vicinity. When inhibitory signals are predominant,
the NK cell will not become activated and the target cell will not be destroyed 84,87,89.
2.2. NK cell receptor gene clusters
NK cell receptors and some of their ligands are encoded by gene clusters on multiple
chromosomes in humans and mice. There are two main gene clusters which contain
genetic sequences encoding NK cell receptors in humans and mice: the leukocyte
receptor complex (LRC) and the natural killer complex (NKC). The latter encodes type
II transmembrane, c-type lectine-related proteins while the LRC encodes members of the
Ig superfamily (IgSF) 90. In humans, the LRC is found on chromosome 19 and it contains
45 genes including families such as the KIRs, leukocyte Ig-like receptors (LIRs), and the
leukocyte associated Ig-like receptors (LAIRs)

91

. The human LRC contains the gene

encoding the natural cytotoxicity-triggering receptor 1 (NKp46, or NCR1) 91. In mice, the
LRC is located on chromosome 7 and, unlike the human LRC, it does not contain the
KIR loci. The murine LRC does, however, contain orthologs of human NCR1 and LAIR1,
as well as NKp46 91,92. The NKC is located on chromosome 12 in humans chromosome 6
in mice

91

. The human NKC contains genes such as NKG2D, NKG2A, NKG2C, NKR-

P1A, AND LLT1 (lectin-like transcript 1, the cognate ligand of NKR-P1A). The mouse
NKC is similar to the human NKC and contains genes such as Nkg2d, Nkg2a, Nkg2c,
Nkrp1, and Clr genes (the cognate ligands of the Nkrp1 family of receptors), and Ly49,
which are orthologues of human KIR 91.
15

Recognition of MHC-I molecules is essential for innate responses of NK cells. NK
cell receptors such as mouse Ly49 receptors, human KIRs, and NKG2/CD94 receptors,
which are conserved across both species, recognize MHC-I molecules 84. Ly49 receptors
are classified as membrane c-type lectin-like receptors and their expression is not limited
to NK cells but they are also expressed on CD8+ T lymphocytes and NKT cells, among
other cell types 93. Ly49 receptors can be either activating or inhibitory. Inhibitory Mouse
Ly49 receptors (Ly49A, Ly49B, Ly49C, Ly49E, Ly49G), which signal through an ITIM,
are similar to human KIRs in that they recognize MHC-I molecules and inhibit NK cell
function 94. Ly49 receptors are essential in preventing autoimmunity and the acquisition
of Ly49 in NK cell development is important in licensing/education

95

. There are some

Ly49 receptors that are activating (Ly49D, Ly49H, Ly49L), and their function is to
trigger the effector NK responses 94. Activating Ly49 receptors use DAP12 for signaling
96

. Humans lack the Ly49 family of receptors but the human KIR receptors are

orthologous to the Ly49 receptors in mice and recognize HLA-A, -B, and -C 97. There are
inhibitory and activating KIR receptors which signal through an ITIM and DAP12
ITAM, respectively 98.
NKG2D is an activating receptor through which NK cells recognize “stressed cells” .
Its gene is in the NKC, and it is expressed on virtually all murine NK cells. This
activating receptor recruits DAP10 or DAP12 adaptor molecules when it recognizes a
cognate ligand such as MHC-I proteins

99

. NKG2D is a type II transmembrane

glycoprotein and it is expressed as a homodimer, therefore it does not heterodimerize
with CD94, like other members of the NKG2 family 99. This activating receptor triggers
NK cell effector functions, occasionally signaling for the secretion of cytokines and

16

chemokines

100

. There are two isoforms of the murine Nkg2d gene including the long

isoform (NKG2D-L) and the short isoform (NKG2D-S). NKG2D-L associates with
DAP10 while NKG2D-S uses both DAP10 and DAP12 adaptor molecules

100

. The

ligands for mouse NKG2D include Rae-1, H60, and Mult1, which all relate with MHC-1
molecules

101

. Human NKG2D only associates with DAP10102. The human NKG2D

receptors recognize ligands which include MICA, MICB, ULBP1, -2, -3, and -4 99. It has
been shown that NKG2D ligands are expressed on tumour cells, which triggers NK cell
effector functions and destruction of the target cells

101

. NKG2D expression on NK cells

renders tumour cells more susceptible to destruction and so they have a decreased
survival rate 103. Tumour cells can decrease NKG2D ligand expression in the presence of
the NKG2D receptor to evade detection by NK cells

104,105

. Some conditions which

induce NKG2D ligand expression include DNA damaging agents, DNA synthesis
inhibitors, and human cytomegalovirus (HCMV) or MCMV infections 104,106,107.
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Leukocyte Receptor Complex (LRC)

Natural Killer Complex (NKC)

Figure 2: Human and Murine Leukocyte Receptor Complex and Natural Killer Complex
Maps are not to scale. The LRC and NKC in humans and mice are shown (not all
receptor genes are shown). Homology between human and mouse receptors is indicated
by the color similarities representing genes.
Reprinted from Trowsdale, J. Genetic and functional relationships between MHC and NK
receptor genes, Immunity 15 (3), (2001), with permission from Elsevier.
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Natural Killer Complex (NKC)

LLT1

Figure 3: NKC in mice and humans
The NKC is located on chromosome 6 in mice and chromosome 12 in humans. The genes
coding for ligands of NKRP1 family receptors are interspersed between the receptor
genes. There is homology in the human and mouse Nkrp1/NKR-P1 and Nkg2/NKG2
families but the human homolog of the Ly49 family is found on the LRC on chromosome
19 and they’re known as the KIR family.
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3. NKR-P1:Clr Receptor:Ligand Family
NKR-P1 receptors are type II membrane glycoprotein receptors which belong to
the C-type lectin family

97

. The first NK cell marker discovered in mice was NK1.1

(NKR-P1C), an activating NK cell receptor, and it is the prototype antigen which defines
mouse NK cells in B6 mice 108. The gene which encodes NK1.1 is Nkrp1c and is found in
the NKC on the mouse chromosome 6 where there is some variation at this locus in
different strains of mice

109

. In 1977, Glimcher et al. first discovered NK1.1 and later a

specific mAb against NK1.1 was developed (PK136 mAb), facilitating the detection and
purification of NK cells 9,110. Since then, there are several other NKR-P1 receptors which
have been identified which are both activating and inhibitory. These include three
activating receptors (NKR-P1A, -P1C, -P1F), two inhibitory receptors (NKR-P1B/D, and
-P1G), and one pseudogene (Nkrp1e) 111,112. In addition to expression on NK cells, NKRP1B has been found on a subset of NKT cells and in most ILC subsets
also found on a subset of T cells

113

. NKR-P1G is

114

.

Remarkably, on the NKC, NKR-P1 receptor genes and the genes of their ligands
(Clr/Clec2) are interspersed and so their inheritance is linked, ensuring that MHC-1independent self-tolerance is preserved

84

. Clr-b was first discovered while Zhou et al.

were investigating bone morphogenesis and they found a gene product which inhibited
osteoclast formation when expressed on osteoblast cells, therefore it was designated
osteoclast inhibitory lectin (Ocil) 115. Concurrently, Plougastel et al. identified a set of Clr
gene products which were encoded by Clec2 genes between mouse Nkrp1a and Cd69 116.
Later on, it was discovered that the ligand for NKR-P1B/D is C-type lectin-related
protein B (Clr-b) and the ligands for NKR-P1G are Clr-d,f,g
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117

. Activating NK cell

receptor, NKR-P1F recognizes Clr-c,d,g 117. Clr-b transcripts were found in many organs
and cells, including the lungs, spleen, BM, thymus, ileum, ovaries, liver, kidneys, and
NK, T, DC, and B cells

35,118

. Clr-f transcripts were only found in the ileum, liver,

kidneys, and NK cells while Clr-g is only expressed on NK cells

116

. Scientists have yet

to discover the partnerships of NKR-P1A and NKR-P1C as well as the remaining Clr
family members.
Humans have a single NKR-P1 gene, NKR-P1A, which encodes the NKR-P1A
inhibitory receptor, which is homologous to the mouse NKR-P1B119. NKR-P1A
recognizes LLT1 and when the receptor and ligand interact, NK cell effector functions
are inhibited
NKC

120

. LLT1’s gene is located in close proximity to the NKRP1A gene on the

121

. Humans also have two NKC C-type lectin-related receptors, NKp65 and

NKp80, that are linked with their ligands KACL and AICL, respectively

122,123

. These

genes have been hypothesized to represent homologs of murine NKR-P1 genes 124.
Activating NKR-P1 receptors lack an ITAM but NKR-P1C contains a charged
transmembrane residue which allows for association with an adaptor molecule that
contains an ITAM

109

. NKR-P1B contains an ITIM which inhibits NK cell effector

functions through SHP-1 phosphatase signaling 125.
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Figure 4: NKR-P1 receptor and Clr ligand families
The NKR-P1 receptor family is located on chromosome 6 in mice and there are 5
receptor members which are known: NKR-P1A, -P1C, -P1F, -P1G, and -P1B/D (left to
right). The receptors represented in green are activating and are associated with a
cytoplasmic ITAM. The receptors in red are inhibitory and are associated with an
intracellular ITIM. Their cognate ligands are depicted, and their association is
represented by an arrow.
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3.1. NKR-P1B:Clr-b
NKR-P1B is an inhibitory NK cell receptor detected on nearly 60% of NK cells in B6
mice

126

. NKR-P1B recognizes Clr-b, which is expressed in many organs, nucleated

hematopoietic cells, and fibroblasts but it is also found on virally infected, stressed, and
tumour cells, resembling the expression pattern of MHC-I

35,127

. Clr-b is essential for

MHC-independent missing-self recognition of “self” cells and also discrimination of
healthy-self/altered-self cells 37. The loss of Clr-b is involved in missing-self recognition
of tumour cells, MCMV-infected cells, and stressed cells 35,128,129. Clr-b-/- and NKR-P1B-/mice were generated and revealed the role of the NKR-P1B:Clr-b axis in regulating
hematopoietic transplant rejection and innate immune responses against cancer and viral
infections

37,46

. NKR-P1B deploys a missing-self response against cells lacking Clr-b

expression but NK cells that lack NKR-P1B expression have damaged missing-self
recognition and cannot recognize target cells that lack Clr-b 46. Rahim et al. made use of
a Eμ-myc transgenic mouse model which develops spontaneous B-cell lymphoma due to
the expression of the c-myc oncogene in B cells. They showed that the myc-induced B
cell lymphoma cells express Clr-b, and they deceptively engage NKR-P1B to evade NK
cell killing. When the NKR-P1B receptor was disrupted, this resulted in delayed tumour
development and slower tumour progression 46. In addition to B cell lymphoma, Clr-b has
been shown to be expressed in many mouse cancer cell lines including mammary,
prostate, colon, melanoma and carcinoma, which indicates that they are immunoevasive
35

.
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4. Cancer immunity and immunosurveillance
NK cell-mediated cytotoxicity plays an essential role in prevention and control of
tumorigenesis. NK cells survey tissues, detect abnormality, and eliminate virus/parasiteinfected cells and transformed cells without prior sensitization. In 2000, a study of the
Japanese general population looking at immunological markers reported that NK cell
cytotoxicity is associated with reduced cancer risk and reduced NK cell activity is
associated with increased risk of tumorigenesis

130

. Many studies since then have shown

that NK cell depletion or reduced NK cell activity is associated with a poor cancer
prognosis but that infiltration of NK cells into tumours yields a much better prognosis in
many carcinomas 131–133. Due to their cytotoxic ability against tumour cells, NK cells are
a prime candidate for anti-cancer immunotherapeutic strategies. Such strategies include
the use of lymphokine-activated killer cells (LAKs), which are NK cells activated with
IL-2, in vitro, or IL-2 injection to activate NK cells in vivo, both of which were
unsuccessful

134,135

. IL-2 injections may be counterintuitive since they favour T

regulatory cells, which suppress cytotoxic CD8+ T cells

136

. Another method of NK cell-

based immunotherapy involves ex vivo expansion and activation of NK cells, which is
promising since it overcomes immunosuppression in a tumour microenvironment. To
culture and expand NK cells for adoptive transfer, cytokines are useful (IL-2, IL-12, etc.)
since they increase the expression of activating receptors on NK cells 137.
Worldwide, cancer is a foremost cause of death, resulting in approximately 10 million
deaths in 2020, with the most cases being breast cancer
than 30% of morbidity in the United States and Canada

138

. Cancer accounts for more

139,140

. Recently, immunotherapy

has become a promising approach in the world of cancer therapy since it employs the
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immune system to treat cancer. Cancer is an extremely heterogenous disease which
differs from tissue to tissue and person to person, which makes the disease difficult to
treat. Understanding the intricacies of cancer, the immune system, and their interaction is
the key to developing novel immunotherapeutic approaches and, hopefully, putting an
end to cancer. Tumorigenesis is a multistep process by which normal cells are
transformed in malignant cells through the acquisition of several biological capabilities,
rendering them resistant to cell death. Tumours acquire six capabilities in their
transformation process, and these are known as the “hallmarks of cancer”. Tumour cells
begin with genomic instability (point mutations, translocations, duplications, deletions)
which leads to changes which allow these cells to (1) sustain proliferative signaling and
141

(2) evade growth suppressors

. This leads to the (3) resistance to apoptosis, (4)

rendering the tumour cells virtually immortal. As the tumours continue to grow, they can
induce (5) angiogenesis, and subsequently (6) metastasize to other tissues

141

. In this last

decade, two other hallmarks immerged thanks to intense research. It was shown that
tumour cells can also (7) reprogram energy metabolism in cancer cells and (8) evade
immune destruction. Additionally, the tumour microenvironment and the interaction
between the tumour cells and the immune system contributes to tumorigenesis 141.
There are several factors which initiate tumorigenesis, including radiation, oxidative
stress, chromosomal alterations (translocations, deletions), or mutations in tumour
suppressor genes or oncogenes 142. Radiation can lead to double stranded breaks in DNA
which leads to mutations in the DNA. ROS and nitric oxide (NO) produce free radicals
and peroxides, leading to cell damage and rendering these the most common agents
which cause oxidative stress

143

. Chromosomal alterations typically occur in regions that
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result in aberrant cell signaling, abnormal expression of transcription factors, and overexpression of oncogenes

142

. Such regions include genes that code for tumour-

suppressors, oncogenes, and tissue-specific promoters such as MYC

142

. Tumour

suppressor genes, such as p53, must have both alleles mutated before they lose their
function and when they are both mutated, they can no longer function to suppress tumour
growth

144

. Oncogenes such as c-Myc or Ras promote cancer progression when they

become mutated. They can endorse cancer hallmarks such as sustaining proliferative
signaling, evasion of growth suppressors, resistance to cell death, and cell
immortalization 141,145,146.
4.1. Cancer immunosurveillance
The understanding of the immune system, its functions, and its components greatly
impacts our understanding of tumourigenesis. The immune system comprises a plethora
of players, each with a unique function. One of these functions was proposed in 1957 by
Sir Frank MacFarlane Burnet who came up with the theory of immune surveillance

147

.

He hypothesized that tumour cell antigens induce an immune reaction against cancer and
wrote that “[i]t is by no means inconceivable that small accumulation of tumour cells
may developand because of their possession of new antigenic potentialities provoke an
effective immunological reaction with regression of the tumour and no clinical hint of its
existence.” 148.
In 1963, evidence arose for the observation that individuals with primary
immunodeficiencies develop cancer

149

. Since then, the scientific world has made leaps

and bounds in the understanding of the role of the immune system in tumorigenesis and
the development of immunotherapeutic methods. There have been many studies which
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provided evidence for Burnet’s hypothesis of immunosurveillance and have shown that a
longer survival and better cancer prognosis is achieved when patients have a higher
number of lymphocytes and NK cells, in cancers of the mammary tissues, prostate,
bladder, and melanoma, among many others

131,150–153

. In mice, it has been shown that

depletion of NK cells is associated with more aggressive tumour growth in tumour
induction models, providing evidence of the immune surveillance of NK cells

154

. Some

types immunotherapy that are used to treat cancer include immune checkpoint inhibitors
such as programmed cell-death-1 ligand-1 (PD-L1) inhibitor, T cell transfer therapy such
as CAR T-cell therapy, mAbs, cancer treatment vaccines, and immune system modulators
to stimulate the immune system 155.
While the immune system is a bulwark against pathologies, it would also present as
an Achille’s heel for cancer treatment since it may facilitate tumour progression by
allowing for the selection of immunoevasive tumours. Tumorigenesis can be presented as
three stages. The first stage is “elimination” whereby pre-cancerous cells are eliminated
by immune cells. The cancer cells which evade elimination enter the second phase
“equilibrium” by which they reach equilibrium with the anti-tumour response. The final
stage is the “escape” stage whereby tumour cells completely escape anti-tumour
immunity and form detectable lesions 156.
Adaptive and innate immune cells work together in the elimination phase to detect
and eliminate a developing tumour before it continues to grow, proliferate, and enter
equilibrium. NK and T cells both play a pivotal role in eliminating pre-malignant cells
156

. NK cells express effector molecules such as IFN-γ and ligands for death receptors,

such as TRAIL and FasL 156,157. Interleukin 12 (IL-12), a cytokine expressed by NK cells

27

and is required for NK cell effector functions, has been shown to be critical for tumour
elimination in many mouse models

156

. In the equilibrium phase some tumour cells

become altered and evade immune recognition. T cells and IFN-γ contribute to control
and maintenance of the progressing tumour in the equilibrium phase. Some studies have
shown that NK-depletion did not accelerate tumour growth, suggesting that adaptive but
156

not innate immunity may be preventing tumour growth beyond the equilibrium phase

.

Tumour cells that make it past all the immune checkpoints can proliferate and form
visible lesions. Immune escape occurs when tumour cells acquire intrinsic and extrinsic
alterations which select for greater survival and/or when immune responses are
dampened. Some intrinsic immunoevasive mechanisms acquired by tumour cells include
MHC-I downregulation to evade recognition by CD8+ T lymphocytes, upregulation of
apoptotic inhibitors such as bcl-xl, and expression of ligands for death receptors, such as
FasL

156

. Extrinsically, tumours can secrete molecules to cause immunosuppression of

immune effector cells such as shedding of NKG2D ligands, which is associated with
advanced cancer and a poor clinical prognosis

158

. Events that lead to decreased immune

response can include immunosuppression by cells in the tumour microenvironment,
immune cell exhaustion, and general immune deterioration due to senescence.
4.2. NK cell-mediated cancer immunosurveillance
NK cells play an important role in controlling tumorigenesis, evidenced by the fact
that an impaired NK cell deficiency has been shown to result in malignancy

159

. In

addition to adaptive effector cells, NK cells contribute to maintenance of homeostasis
through their cytotoxicity and cytokine production. NK cell receptors NKG2D and Ly49
are majorly involved in cancer immunosurveillance. Even if tumour cells express MHC-I,
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NKG2D expression on tumour cells can overcome the inhibitory signals and if MHC-I is
downregulated on tumour cells, Ly49 receptor can recognize the missing ligand and
deploy a missing-self response by which tumour cells are killed

101,160

. NKG2D-deficient

mice are susceptible to tumorigenesis and Ly49-deficient mice cannot control tumour
growth and metastasis 41,161. Tu et al. have shown that tumours from Ly49+/+ mice have a
phenotype of higher MHC-I expression when compared with tumours from Ly49deficient mice which is evidence for immunoediting of tumour cells in the Ly49+/+,
selecting for the survival of those cells with the highest MHC-I expression 41. NKp46 is
an activating NK cell receptor and the loss of NKp46 in mice is associated with the
inability to control the growth and metastasis of lymphoma and melanoma cell lines
162,163

.

4.3. NK cells in breast cancer
The highest number of cancer cases worldwide are attributed to breast cancer

164

.

Among cancer deaths in women, breast cancer ranks second. Although there is significant
improvement in detection of primary tumours and progress of clinical outcomes due to
screening methods, conventional therapies do not address the risk of relapse and
metastasis of the disease. Additionally, tumours are extremely heterogenous and some
types are drug and radiation resistant, which presents major challenges to treatment of
these types of cancer 165.
Breast cancer is categorized histologically and based on molecular markers.
Histologically, the two categories into which breast cancer may be classified are: in situ
carcinoma and invasive carcinoma

165

. In situ carcinomas are sub-classified as ductal

(DCIS) or lobular (LCIS). DCIS are additionally sub-classified based on tumoral
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qualities: comedo, cribriform, micropapillary, or solid

166

. Invasive carcinomas are

heterogenous and they are classified into the following subtypes: infiltrating ductal (IDC,
most common), invasive lobular, ductal/lobular, mucinous, tubular, medullary, and
papillary

165

. IDC is further subclassified into three grades: well-differentiated to poorly

differentiated (grade 1-3), respectively 166.
Some molecular markers have been used to classify breast cancer subtypes and
include estrogen receptor positive (ER), progesterone receptor positive (PR), and human
epidermal growth factor receptor 2 positive (Her2, also known as ErbB2)

165

. Breast

cancers that are triple negative (ER-, PR-, and Her2- negative) grow much faster and are
more invasive than other types of breast cancer and show a poor prognosis 165.
Tumour infiltration by immune cells such as NK cells and CD8+ T cells is essential
in the prevention of the progression of cancer

167

. Current methods of immunotherapy

target adaptive immune cells through immune checkpoint inhibitors such as CTLA-4 and
anti-PD1/ anti-PD-L1

168

. Innate immune cells such as natural killer cells are highly

involved in tumour infiltration and anti-tumoral activity. It has been shown that NK cell
depletion in mice results in increase susceptibility to cancer and reduced NK cell activity
in cancer patients leads to a poor cancer prognosis

131,132,154

. Hence, NK cells have a

promising therapeutic potential.
4.4.Ly49 receptors in breast cancer
In 2017, Tu et al. published a manuscript wherein they studied the impact of the
inhibitory Ly49 receptor in breast cancer

41

. They used the E0771 medullary

adenocarcinoma cell line to study the role of Ly49 in tumour control. They knocked out
MHC-I (H-2Kb and H-2Db) in E0771 cells using CRISPR-Cas9 and incubated WT and
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MHC-I-deficient E0771 cells with WT and Ly49-deficient adherent lymphokine (IL2)activated killer cells (ALAKs) to observe whether there would be a difference in the
killing of MHC-I WT and KO E0771 cells. They found that MHC-I-deficient E0771
cells were much more susceptible to killing by WT ALAKs than WT E0771 cells

41

.

When they injected WT and MHC-I-deficient E0771 cells into the mammary fat pad of
Ly49 WT and KO mice, they found that tumours from MHC-I-deficient E0771 cells grew
more rapidly in Ly49-deficent mice than WT mice 41. Additionally, they used an MMTVPyVT mouse model of spontaneous tumour development on a WT and Ly49-deficient
background to observe the effects of the lack of the receptor on tumour growth and
development. They perceived that mice which lack the Ly49 receptor began developing
palpable tumours earlier and those tumours grew faster than the tumours from their WT
counterparts 41. They were also able to observe tumour immunoediting of tumours. They
observed that early stage Ly49-deficient tumours were comparable with the WT tumours
but end-stage tumours from Ly49-deficient mice were found to have lower expression of
MHC-I, which may be attributed to avoidance of the cytotoxic effects CD8+ T cells. All
these results provided evidence for the role of the inhibitory receptor, Ly49, in tumour
immunosurveillance and immunoediting in a model of breast cancer.
4.5.NK cell exhaustion in cancer
Tumours and chronic infections can contribute to a phenomenon called “immune cell
exhaustion” where immune cells become dysfunctional, especially in terms of their
effector functions
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. One study in murine models showed that tumour-infiltrating NK

cells produced fewer effector cytokines
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. In cancer patients, NK cells showed reduced

effector function, attested by lower levels of perforin, granzymes, TRAIL, and FasL
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.

Other studies showed that tumour-infiltrating NK cells showed decreased cytotoxic
activity, decreased production of perforin, granzyme B, CD107a, and IFN-γ compared
with NK cells from without the tumour

172,173

. Interestingly, in mice when normal NK

cells are adoptively transferred into mice with leukemia, the transferred NK cells rapidly
lose IFN-γ production and effector function 174.
Exhausted NK cells exhibit distinct phenotypes which differ from healthy NK cells.
Gill et al. were the first to describe NK cell exhaustion in their study of adoptive transfer
of NK cells in lymphoma models. They traced the luciferase-expressing normal NK cells
in the lympho-depleted mice and found that the healthy NK cells rapidly accumulate at
the tumour sites but fail to attack the tumour due to downregulation of effector functions
174

. Moreover, these exhausted NK cells exhibit a downregulation of transcription factors

Eomes and T-bet

174

. When they forced expression of Eomes in adaptively transferred

NK cells, this partially reversed NK cell exhaustion, as evidenced by a reduction in
tumour burden in the tumour mice

174

. Gill et al. also found that tumour-infiltrating NK

cells exhibited a downregulation of activation receptors NKG2D and NK1.1 as well as
integrin CD49b compared with splenic NK cells

174

. Subsequent studies showed that

NKG2D is downregulated on NK cells in patients with diverse kinds of cancers such as
pancreatic, gastric, and breast cancer

171,173

. In addition to NKG2D downregulation,

CD16 and NKp46 were also shown to be downregulated in exhausted NK cells

173,175

.

Furthermore, inhibitory receptors such as PD-1 are overexpressed on exhausted NK cells
in patients with Kaposi sarcoma, and various other kinds of cancers

176

. In patients with

hepatocellular carcinoma, inhibitory receptor NKG2A, is overexpressed, which is an
indicator of a poor prognosis in these patients
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177

. IL-15 is required for NK cell

maturation. In tumour bearing mice, exhausted NK cells exhibited downregulation of IL15 expression, which would hinder mature NK cell effector functions 178.

5. Myeloid-Derived Suppressor Cells
Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of cells
which originate from monocytic or granulocytic lineages. Hematopoietic stem cells
differentiate into common lymphoid progenitors to generate T cells, B cells, NK cells, or
common myeloid progenitors. Depending on the factors present, common myeloid
progenitors further differentiate into monocytes, granulocytes, macrophages, dendritic
cells, erythrocytes, or megakaryocytes

179

. Granulocytes and monocytes are the major

populations of myeloid cells derived from the BM and, in vivo, macrophages expand in
situ while dendritic cells differentiate from their BM precursors

180

. In pathological

situations such as cancer, tumour-associated macrophages (TAMs) and inflammatory
DCs arise from BM-derived monocytes
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.The fate and phenotype of MDSCs is

determined by their developmental origin. MDSCs can arise from several pathological
conditions such as cancer and obesity and their function, as their name suggests, is
immunosuppressive. The designation of these myeloid cells with immunoregulatory
function was initially introduced to scientific literature in 2007 in studies involving
tumour-bearing mice, and since then, the activity of these cells has become more
apparent as research

182

. MDSCs fit into two general categories of cells: granulocytic or

polymorphonuclear (PMN-MDSCs) and monocytic MDSCs (M-MDSCs). PMN-MDSCs
are comparable to neutrophils in their morphology and phenotype but M-MDSCs are akin
to monocytes

183

. The granulocyte-macrophage colony-stimulating factor (GM-CSF)
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drives myelopoiesis and G-CSF stimulates granulocyte differentiation while M-CSF
induces monocyte differentiation 184. GM-CSF, G-CSF, and M-CSF are overexpressed in
cancer and this may contribute to MDSC development

185

. MDSCs are rarely detected at

the early stages of cancer but some cells with similar genomic MDSC characteristics are
detected

186

. It is suggested thar there are two groups of signals that govern MDSC

accumulation: the group is responsible for the expansion of immature myeloid cells and
the second is essential for their pathologic activation 187. MDSCs are a marker for cancer
and a better understanding of MDSCs will prove beneficial to its targeting for therapeutic
purposes.
5.1. MDSC phenotype and activity
MDSCs are relatively difficult to distinguish from monocytes and neutrophils. PMNMDSCs in mice are defined as CD11b+Ly6G+Ly6Clo. CD11b is a myeloid lineage
marker and Ly6G and Ly6C are cell membrane molecules which make up GR1, the
granulocyte marker

188

.. PMN-MDSCs greatly resemble tumour-associated neutrophils

(TANs) which are also a heterogenous population of cells and include anti-tumour
neutrophils and pro-tumour neutrophils (which are, essentially, PMN-MDSCs)

190

. M-

MDSCs, in mice, are defined as CD11b+Ly6G-Ly6Chi and they also express CD115,
CCR2, and CD49d (integrin alpha-3)

191

. Healthy monocytes express CD11c (integrin

alpha-X) and MHC-II, which are not expressed by M-MDSCs 192.
The primary activity of MDSCs distinguishing from monocytes and neutrophils is
that MDSCs are immunosuppressive and are involved in tumour progression and
maintenance. MDSCs participate in inflammatory process inhibition at the site of
inflammation as their activity in inflammatory pathologies is evident. In conditions of
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chronic inflammation, such responses would be considered beneficial since long-lasting
immune activation would worsen the condition

193

. However, MDSC accumulation is

known to be involved in aggravation of pathological conditions such as cancer. MDSCs
counter immune responses of innate and adaptive effector cells and produces an
environment conducive to tumour growth and metastasis. M-MDSCs have a greater
suppressive ability than PMN-MDSCs and both use different suppressive mechanisms.
Some mechanisms used by MDSCs to suppress immune activity include factors such as
upregulation of ROS, NO, arginase 1 (ARG1), and prostaglandin E2 production (PGE2)
194

. One study showed that tumour-infiltrating MDSCs use fatty acid-β oxidation (FAO)

as an energy source which suggests that FAO inhibition would affect MDSC suppressive
functions which is a potential avenue for immunotherapy 195.
5.2. MDSCs in cancer
Many studies pertaining to the role of MDSCs in cancer have been conducted through
experiments which analyze MDSC populations in cancer patients. Studies show that there
is a positive correlation between cancer stage and severity in many cancers such as breast
cancer and melanoma, and the percentage of MDSCs in the patient’s peripheral blood
194,196

. The number of M-MDSCs in patients with breast cancer, is indicative of metastatic

status

197

. Furthermore, the number of circulatory MDSCs in cancer patients with solid

tumours was found to be an indicator of poor results

198

. Overall, MDSCs are associated

with bad outcomes in all cases.
Pertaining the activity of MDSCs in breast cancer progression, MDSCs use many
mechanisms to suppress immune activity in the tumour microenvironment. For example,
MDSCs facilitate immune evasion of tumour cells through methods such as the
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expression of the programmed death-ligand 1 (PD-L1), which binds PD-1 (found on T
and B cells) to achieve inhibition of the immune cells and thus suppress immune response
against cancer cells

199

. They also secrete TGF-β, inducing Treg cells, which suppress

CD8+ T cell cytotoxicity, and is suppressive to NK cells

199

. In peripheral lymphoid

organs, MDSCs require direct cell-to-cell signaling in order to mediate immune
suppression whereas in tumours, MDSCs use agents such as cytokines in order to
suppress immune activity, not requiring direct contact

200

. The predominant type of

MDSC in the peripheral blood of breast cancer patients is PMN-MDSCs. IL-17 produced
by tumour infiltrating γδ T cells, activates PMN-MDSCs and at the same time, inhibits
cytotoxic CD8+ T cells, which deteriorates outcomes for patients

201

. Interestingly, one

study using the murine model showed that MDSCs specifically reduce NK cell activity in
the pre-metastatic niche was reduced as the number of CD11b+Ly6CmedLy6G+ myeloid
cells increased 202.
MDSCs are a promising therapeutic target since they are known to be involved in the
development and progression of many cancer types, including breast cancer. Many
studies have yielded hopeful results in terms of MDSC reduction, and they focus mainly
on inhibiting the cytokines and chemokines which are involved in the differentiation of
MDSCs. For instance, anti-CCL5 was found to promote T-cell proliferation and decrease
MDSC activity in triple negative breast cancer

203

. Interestingly, one study showed that

curcumin is a potent inhibitor of IL-6, a cytokine produced by tumour cells in triple
negative breast cancer, and helps reduce the number of MDSCs in patients
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.

HYPOTHESIS AND RESEARCH OBJECTIVES
Previous work in our lab investigated the role of NKR-P1B in NK cell function
and development by producing NKR-P1B-deficient B6 mice and studying the
effectiveness of NK cells against myc-induced B cell lymphoma 46. The lack of Clr-b
recognition by NKR-P1B receptor triggers a missing-self response against the target
cells. When NKR-P1B is missing from NK cells, there is an impaired missing-self
response and these NK cells cannot recognize missing Clr-b. Additionally, they found
that NKR-P1B-deficient mice were more resistant to B cell lymphoma development in
the Eμ-myc transgenic model of spontaneous B cell lymphoma46.

The NKR-P1B-

deficient mice developed tumours later and their progression was slower than their WT or
heterozygous counterparts46. Clr-b is expressed on multiple cancer cell types, suggesting
the importance of NKR-P1B:Clr-b in tumour immunosurveillance, independent of MHCI recognition. Based on this finding in the leukemia model, we were prompted to see
whether NKR-P1B expression plays a similar role in a solid tumour, namely breast
cancer.
We hypothesize that the expression of the mouse NKR-P1B receptor on NK cells,
and its cognate ligand, Clr-b, on tumour cells play a key role in the immunosurveillance
of solid tumours, such as mammary tumours in mice. In this project, we aim to determine
the role of NKR-P1B:Clr-b recognition in mammary tumour immunosurveillance of
MMTV-PyVT mice and E0771 cell-induced mammary tumours.
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CHAPTER 2: MATERIALS AND METHODS

1. Mouse models
MMTV-PyVT transgenic mice [strain: B6.FVB-Tg(MMTV-PyVT)634Mul/LellJ] and
C57BL/6 (B6) were obtained from The Jackson Laboratories . NKR-P1B-deficient mice
on a B6 background (NKR-P1BB6-deficient) were previously generated by Rahim et al.
46

. MMTV-PyVT mice expressed polyoma virus middle T antigen under the control of

the mouse mammary tumour virus promoter and female mice develop spontaneous
mammary tumours

205

. Male MMTV-PyVT mice were bred with female NKR-P1B

knockout mice. The NKR-P1B+/- progeny were either positive or negative for the
MMTV-PyVT transgene. Subsequently, MMTV-PyVT+ NKR-P1B+/- males were bred
with NKR-P1B+/- females to obtain MMTV-PyVT+ and either NKR-P1B+/+, NKR-P1B+/-,
or NKR-P1B-/-. The female MMTV-PyVT+ NKR-P1B+/+ and MMTV-PyVT+ NKR-P1B-/mice were monitored twice a week for tumour development with an onset of the first
palpable tumour at around 108 days, on average. Tumour size was measured using a
digital caliper. Tumour size was recorded as the average two separate diameter
measurements. When tumours exceeded 15 mm in diameter, the mice were euthanized,
and the tumours were dissected for analysis. Spleens from each tumour-bearing mouse
was also dissected for subsequent experiments. These mice were used for mammary fat
pad injection experiments.
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2. Cell lines
The E0771 cell line originated from a spontaneously arising medullary breast
adenocarcinoma in a C57BL/6 mouse

206

. The E0771 cells used in these experiments

were kindly provided by Dr. Andrew Makrigiannis from Dalhousie University. The cells
were grown in Dulbecco’s Modified Eagle Medium (DMEM) with supplements of 10%
FBS and 1% Penicillin-Streptomycin (referred to as complete DMEM, or cDMEM). The
cells were kept at 37°C and 5% CO2.
3. Clr-b gene CRISPR knockout
Clr-b-deficient E0771 cells were generated using the CRISPR-Cas9 system. A 20
base pair guide RNA (gRNA) sequence was designed using the gRNA design tool,
CHOPCHOP (https://chopchop.cbu.uib.no/), targeting the murine c-type lectin domain
family 2 member D (clec2d), which codes for Clr-b. The gene is found on chromosome 6
and it contains 5 exons. The gRNA sequence (5’CTACCTATGCTTAGTCCCAC 3’)
designed targets DNA in the first exon and was selected based on the fewest predicted
off-targets in the rest of the genome. The gRNA was ligated into the targeting vector,
pSpCas9(BB)-2A-Puro (PX459) V2.0 was purchased from Genscript. The plasmid was
transformed into competent Stbl3 strain of E. coli by heat shocking the bacteria with 2 μL
(100 ng/μL) of plasmid DNA at 42℃ for 120 seconds. The Stbl3 E. coli were plated with
ampicillin (100 μg/mL) and overnight cultures were grown from colonies, picked from
agar plates, in LB broth with 100 ng/μL of ampicillin. Plasmid DNA was extracted using
the Qiagen miniprep protocol. The resultant DNA was diagnostically digested using a
SacI restricting enzyme to determine the presence of the plasmid. The plasmid-containing
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DNA was transfected into E0771 cells using JetOptimus transfection reagent as per the
manufacturer’s instructions. Transfected cells were grown in cDMEM, and media was
enriched with puromycin at 0.8 μg/mL. Transfected colonies were picked using sterile
filter paper soaked in 0.25% Trypsin-EDTA and transferred to 96-well plates containing
cDMEM with 0.8 μg/mL puromycin. Single-cell clones were grown in 10 cm plates and
then harvested using 0.25% Trypsin-EDTA and Clr-b-/- cells were identified using
antibody labelling and cell sorting. Cells were expanded in 96-well plates as single cells
and checked for the absence of Clr-b using flow cytometry analysis.
4. Tumour analysis
Female MMTV-PyVT mice at end point (tumour ≥ 15mm) were sacrificed and their
tumours and spleens dissected for tumour-infiltrating lymphocyte analysis. Tumours were
chopped into small pieces and incubated at 37℃ for 30 minutes in 5mL digestion
medium (5mL serum-free RPMI + 200 μg/mL collagenase D + 20 μg/mL DNase1).
Digestion was terminated by adding EDTA at 1 mM concentration to each dissociated
tumour. To obtain single-cell suspensions for analysis, tumours were then passed through
a 70 μm cell strainer. Spleens from respective mice were dissociated by crushing them
between two glass microscope slides in phosphate buffered saline, and the cell
suspensions were obtained. Red blood cells were lysed using Ammonium-ChloridePotassium (Ack) lysis buffer for 5 minutes. Tumour and spleen suspensions were
resuspended in 1x PBS. Tumour cells and splenocytes were counted using a
hemocytometer and 2 x 106 cells were stained with antibodies as described below.
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5. Antibodies and flow cytometry
Surface staining of TILs and splenocytes was performed using 2 x 106 cells for each
sample. Cells were incubated in unconjugated, fluorophore-conjugated , or biotin
conjugated primary antibody at 4℃ in the dark for 20 minutes at the concentrations
indicated below at 4℃ in the dark for 20 minutes. Subsequently, cells stained with
unconjugated or biotin-conjugated primary antibody were incubated in fluorophoreconjugated or streptavidin-conjugated secondary antibody at the concentrations indicated
below at 4℃ in the dark for 20 minutes. FACS buffer ( was used to resuspend cells for
flow cytometry analysis. Intracellular staining for EOMES, TBET, and Granzyme-B was
done using affixation and permeabilization reagents following manufacturer’s
instructions. Mean fluorescence intensity (MFI) of Clr-b expression in tumour cells and
splenocytes was normalized to MFI of respective samples stained with secondary-alone
stain.
Analysis of CRISPR-mediated Clr-b-/- E0771 cells:
Table 1: Staining of Clr-b on E0771 cells
Antibody

Colour

Ratio

4A6 (anti-Clrb)
Anti-rat IgM

N/A

1:400

PE

1:200

The following tables represent the antibody used to stain cells for flow cytometry
analysis of tumour-infiltrating lymphocytes:
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Stain 1:
Table 2: Stain 1 – Surface stain, primary antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

NK1.1

PE 594

1:100

TCRβ

BV510

1:200

CD49a

PE

1:100

CD49b

PE-Cy7

1:100

2D12-Biotin

N/A

1:200

FVD

APC-Cy7

1:500

Table 3: Stain 1 – Surface stain, secondary antibodies
Antibody

Colour

Ratio

Streptavidin

APC

1:200

Table 4: Stain 1 – Intracellular antibodies
Antibody

Colour

Ratio

EOMES

APC

1:200

TBET

PerCP Cy5.5

1:100

Granzyme-B

BV421

1:500

Stain 2:
Table 5: Stain 2 – Primary antibodies
Antibody

Colour

Ratio

CD45

AF700

1:300

GR1

FITC

1:100

CD11b

PerCP Cy5.5

1:100

4A6 (Clr-b)

PE

1:400

FVD

APC-Cy7

1:500
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Table 6: Stain 2 – Secondary antibody
Antibody

Colour

Ratio

Anti-rat IgM

PE

1:200

Table 7: Stain 2 – Secondary antibody alone control
Antibody

Colour

Ratio

CD45

AF700

1:300

GR1

FITC

1:100

CD11b

PerCP Cy5.5

1:100

FVD

APC-Cy7

1:500

Cells were analyzed using the BD LSR Fortessa™ X-20 analyzer using the BD
FACSDiva™ Software. Flow cytometry data was analyzed using FlowJo™ software
from BD Biosciences.
6. Mammary fat pad injections
Groups of WT female mice were injected with 5x104 E0771 or CRISPR-mediated
Clr-b knockout E0771 cells in the mammary fatpad. To perform the injections, mice were
anaesthetized with 2.5% isoflurane gas in 1 L/min oxygen for 2-3 minutes. Using a 28G
insulin syringe (Becton Dickinson), 5x104 cells in 100 μL sterile PBS was injected into
the 4th mammary gland fatpad. The mice were monitored weekly post injection for
palpable tumours. Tumour measurements (diameter) were obtained twice a week using a
digital caliper.
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7. Statistical analysis
Statistical analyses were performed using Microsoft Excel or GraphPad Prism
Software. Statistical significance was determined by virtue of a two-tailed student T-test
and log-rank test (for tumour-free survival) with a cut-off P value of 0.05 [P<0.05(*), P
< 0.01(**), P<0.001(***)]. Results which were not significant were not designated.
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CHAPTER 3: RESULTS
1. Nkrp1b-/- MMTV-PyVT mice develop tumours earlier than their WT counterparts.
To understand the role of NKR-P1B:Clr-b in mammary tumour immunosurveillance,
the first question to ask was concerning the effect of the absence of the receptor on
tumour onset and development. To answer this question, we measured tumour onset of
mammary tumours in the WT and NKR-P1B-deficient MMTV-PyVT+ mice. We
subsequently measured tumour growth to gauge the tumour growth rate of each subset of
mice. MMTV-PyVT mammary tumour cells, identified as CD45- cells isolated from the
mammary tumours, do not express Clr-b (Figure 1A), which should make them more
susceptible to NKR-P1B-mediated missing-self recognition by NK cells. Our data
indicates that the WT MMTV-PyVT+ mice remain tumour-free longer than the NKRP1B-deficient mice (Figure 1B). NKR-P1B-deficient mice develop tumours significantly
earlier than the WT mice, indicating that NK cells from the NKR-P1B-deficient mice are
not able to recognize their missing cognate Clr-b ligand and, therefore, cannot deploy a
missing-self response against MMTV-PyVT mammary tumours (Figure 1C).
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Figure 5: Nkrp1b-/- MMTV-PyVT mice develop tumours earlier than their WT
counterparts.
A, left histogram: CD45+ TILs express Clr-b (solid line) compared with the isotype
control (shaded area). Right histogram: Cell surface expression of Clr-b on mammary
tumour cells of MMTV-PyVT mice. Staining with the secondary antibody alone was
used to assess non-specific background staining (shaded). B, the time of palpable
mammary tumour appearance and percentage of tumour-free mice were assessed for
MMTV-PyVT transgenic mice on a wild-type (NKR-P1B+/+) (black line, n=14) and
NKR-P1B-deficient (NKR-P1B-/-) (red line, n=30) backgrounds. P=0.03. C, the first
palpable mammary tumour detected in the female mice was measured weekly in MMTVPyVT transgenic female mice on an NKR-P1B+/+ (black lines, n=14) and NKR-P1B-/(red lines, n=30). Each line represents a single tumour in a single mouse.
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2. There is an increase in the frequency of EOMES- tumour-infiltrating NK cells in
tumours of Nkrp1b-/- MMTV-PyVT mice.
Next, we asked whether the tumour-infiltrating lymphocyte proportion was altered in
tumours of NKR-P1B-deficient mice compared with WT mice. To answer this question,
we isolated and analyzed tumour-infiltrating lymphocytes (TILs) and splenocytes from
WT and NKR-P1B-deficient MMTV-PyVT+ mice. We stained the TILs and splenocytes
using various cell-surface markers to determine the phenotype of NK cells and innate
lymphoid cell populations. We analyzed TILs in tumours of different stages. Large
tumours were defined as being >1cm, medium tumours were 0.5-1cm, and small tumours
were defined as <0.5cm.
EOMES (Eomesodermin) expression distinguishes different NK cell subsets, as well
as the ILC1 cells. EOMES is a T-box transcription factor which is required for NK cell
maturation and mice lacking Eomes and T-bet (another T-box transcription factor
implicated in NK cell development), fail to develop NK cells

207

. Conventional NK cells

are generally EOMES+ and ILC1s are EOMES-. However, NK cells have been shown to
lose EOMES expression after experiencing immunological exhaustion during anti-tumour
immune responses174. First, we looked at the proportion of EOMES+ NK cells, identified
as CD45+ NK1.1+TCRβ- cells in the TILs from the WT and KO mice. We observed that
the proportion of EOMES+ NK cells is decreased in the tumours from KO MMTV-PyVT
mice (Figure 2A). When we examined the phenotypic difference of TIL populations
between stages of tumour development (>1cm, 0.5-1cm, and <0.5cm), we observed that
there is an increase in the proportion of EOMES+ NK cells as tumours progress in size in
the WT mice (Figure 2B). In tumours of the KO mice, there is a decrease in EOMES +
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NK cells as the tumour progresses from small to large (Figure 2B). Between the tumours
from WT and KO mice, there is a significantly larger proportion of EOMES + NK cells in
the tumours of WT mice (P<0.05) (Figure 2B). Consequently, the proportion of EOMESNK cells is greater in the tumours from KO mice compared with WT mice (Figure 2C).
There is a significantly larger proportion of EOMES- NK cells in large tumours from NO
mice compared with tumours from WT mice (Figure 2C).
We also compared proportions of EOMES+ and EOMES- NK cells in spleens of
WT and KO MMTV-PyVT mice to determine if there are systemic changes in NK cell
phenotype in the tumour-bearing mice (Figure 2D). These were compared to the spleens
from non-transgenic WT and KO mice, which do not develop mammary tumours. NK
cells in mice with no tumours are mostly EOMES+ (Figure 2D). However, in tumourbearing mice, there is a significant decrease in the proportion of EOMES+ NK cells and a
corresponding increase in EOMES- NK cells. We did not observe a significant different
in the EOMES+ and EOMES- NK cells subsets from the spleens of tumour-bearing WT
and KO mice (Figure 2E and F). These findings demonstrate that NK cells infiltrating
mammary tumours in mice lose expression of EOMES, which is accelerated in the NKRP1B-deficient mice. This correlates with the higher tumour susceptibility in the NKRP1B-deficient mice (Figure 1).
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Figure 6: Loss of EOMES expression in tumour-infiltrating NK cells in Nkrp1b-/- MTVPyVT mice.
A, comparison of WT and Nkrp1b-/- tumour-infiltrating lymphocytes of MMTV-PyVT
mice. Gating on CD45+NK1.1+TCRβ-EOMES+ for NK cells and CD45+NK1.1+TCRβEOMES- for ILC1/NK cells. B and C, graphical representation of mean EOMES+ (B)
and EOMES- (C) NK cell proportions in WT and KO tumours >1cm (L), 0.5-1cm (M),
<0.5 cm(S). NKR-P1B WT tumours: L, n=5; M, n=3; S, n=5. NKR-P1B KO tumours: L,
n=13; M, n=13; S, n=15. P < 0.05. D, comparison of splenocytes of tumour-bearing WT
and Nkrp1b-/- MMTV-PyVT mice. Gating strategy is same as in A. E and F, graphical
representation of mean EOMES+ (E) and EOMES- (F) NK cells in spleens from WT and
KO MMTV-PyVT mice and non-transgenic mice without tumours. NKR-P1B WT
MMTV-PyVT+ spleens: n=5. NKR-P1B KO MMTV-PyVT+ spleens: n=14. WT nontransgenic spleens: n=4. KO non-transgenic spleens: n=5. WT transgenic vs nontransgenic spleens: P<0.01. KO transgenic vs non-transgenic spleens: P<0.05.
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3. Both the EOMES+ and EOMES- NK cell subsets in MTV-PyVT tumours express
NKR-P1B.
NKR-P1B is an inhibitory receptor expressed on NK cells and certain other subsets of
immune cells such as lamina propria-associated γδT cells, ILC1s, ILC3s, and ILC2s

208

.

NKR-P1B is expressed in approximately 60% of NK cells in the lymphoid organs. We
looked at NKR-P1B expression in tumour-infiltrating NK cells in MMTV-PyVT mice
(Figure 4A). We found that both the EOMES+ and EOMES- NK cells subsets express
NKR-P1B and that their expression does not significantly differ according to the stage of
tumour progression (Figure 4B). As expected, there was no expression of NKR-P1B in
the KO NK cells and could serve as an ideal model to study the role of this receptor in
NK cell-mediated anti-cancer responses in the mouse mammary tumours.
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Figure 7: Tumour-infiltrating NK cell in MTV-PyVT mammary tumours express NKRP1B.
A, expression of NKR-P1B in NK cells from WT and Nkrp1b-/- mammary tumours.
Expression of NKR-P1B in both EOMES+ and EOMES- subsets are shown. B, graphical
representation of mean frequency of NKR-P1B+ NK cells in both the EOMES+ and
EOMES- NK cell subsets from WT mammary tumours >1cm (L, n=5)), 0.5-1cm (M,
n=3), <0.5 cm(S, n=5).
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4. Tumour-infiltrating lymphocytes of Nkrp1b-/- MTV-PyVT tumours have altered
CD49a and CD49b phenotypes.
CD49a (integrin ɑ1β1) and CD49b/DX5 (α2β1) are cell-surface integrins which are
expressed on a subset of ILC1s and NK cells , respectively the majority of NK cells in
circulation and in lymphoid organs express CD49b, while tissue-resident NK cells
express CD49a. We looked for the expression of CD49a and CD49b on tumourinfiltrating NK cells and our preliminary findings show a substantial level of CD49a+ NK
cells in the mammary tumours from MMTV-PyVT mice (Figure 3 A and D). Within the
EOMES+ (Figure 3B and C) and EOMES- (Figure 3E and F) NK cell subsets in tumours
at different stages of progression, we observed that in the WT mice, there is an increase
in the CD49a+ NK cell frequency in the larger tumours. Conversely, in the KO mice,
there is a decrease in the CD49a+ NK cell frequency in the larger tumours. These
preliminary findings demonstrate that tumour-infiltrating NK cells in mammary tumours
are phenotypically different from circulating NK cells and more closely resemble tissueresident NK cells. Moreover, the proportion of tissue-resident NK cells in the mammary
tumours is affected by the NKR-P1B receptor.
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Figure 4: Tumour-infiltrating lymphocytes of Nkrp1b-/- MTV-PyVT tumours have
altered CD49a and CD49b phenotypes.
A, comparison of CD49a+ and CD49b+ subsets within the EOMES+ NK cells in tumours
from WT and Nkrp1b-/- MMTV-PyVT mice. Gating on CD45+NK1.1+TCRβEOMES+CD49b+ and CD45+NK1.1+TCRβ-EOMES+CD49a+ NK cells. B and C,
graphical representation of mean frequency of EOMES+CD49b+ (B) and EOMES+CD49b(C) NK cells in WT and KO tumours >1cm (L) and <0.5 cm(S). WT tumours: L, n=1; S,
n=1. NKR-P1B KO tumours: L, n=8; S, n=9. D, comparison of CD49a+ and CD49b+
subsets within the EOMES- NK cells in tumours from WT and Nkrp1b-/- MMTV-PyVT
mice. Gating on CD45+NK1.1+TCRβ-EOMES-CD49b+ and CD45+NK1.1+TCRβEOMES-CD49a+ ILC1s. E and F, graphical representation of mean frequency of
EOMES-CD49a- (E) and EOMES-CD49a+ (F) NK cell in WT and KO tumours >1cm (L)
and <0.5 cm(S). WT tumours: L, n=1; S, n=1. NKR-P1B KO tumours: L, n=8; S, n=9.
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5. Granzyme-B-mediated NK cell activity is reduced in Nkrp1b-/- tumours compared
with their WT counterparts.

EOMES is required for NK cell development and function. Since we observed a loss
of EOMES expression in tumour-infiltrating NK cells, we checked NK cell activity in
tumours from WT and KO mice. We looked at the expression of an NK cell effector
molecule, granzyme B to gauge cytotoxicity. We compared granzyme B expression in the
WT and KO NK cells (EOMES+ and EOMES- subsets) in tumours >1cm, 0.5-1cm, and
<0.5cm. In the WT tumours, granzyme B expression was detected predominantly in the
NKR-P1B+ NK cells in the EOMES+ subset, and in both the NKR-P1B+ and NKR-P1BNK cells in the EOMES- subsets (Figure 5A). The frequency of granzyme B+ NK cells
tended to be higher in early-stage tumours (<0.5-1cm) compared with late-stage tumours
(>1cm) (Figure 5B). Granzyme B+ frequency was also found to be higher in WT
EOMES+ NK cells compared with KO NK cells. In the EOMES- subset, the frequency of
granzyme B+ cells remained relatively constant across NKR-P1B genotype and tumour
size (Figure 5C). Therefore, tumour-infiltrating NK cell activity is reduced tumours from
NKR-P1B-deficient mice compared with WT mice, which correlates with increased
frequency of EOMES- NK cell phenotype and higher susceptibility to mammary tumour
onset in the KO mice. Although, this appears to contradict the expected inhibitory
function of NKR-P1B receptor, the data suggests that NKR-P1B may play a more
complex role in homeostasis of anti-tumour immunity mediated by NK cells in the
MMTV-PyVT mammary tumour model.
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Figure 8: Granzyme-B-mediated NK cell activity is reduced in tumours from Nkrp1b-/mice compared with their WT counterparts.
A, comparison of WT and Nkrp1b-/- tumour-infiltrating NK cells (EOMES+ and
EOMES- subsets) from large (>1cm) and small (<0.5) tumours of MMTV-PyVT mice. B
and C, graphical representation of mean percentages of granzyme B+ (GzmB+) EOMES+
(B) and EOMES- (C) NK cells in WT and KO tumours >1cm (L), 0.5-1cm (M), <0.5
cm(S). WT tumours: L, n=5; M, n=3; S, n=5. NKR-P1B KO tumours: L, n=13; M, n=13;
S, n=15.
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6. MDSC infiltration into tumours of Nkrp1b-/- MTV-PyVT mice is greater than WT
mice.

To further decipher the mechanisms by which NK cell activity is regulated in the
mammary tumours, we analyzed myeloid-derived suppressor cells (MDSC), which are
immunosuppressive cells in the tumour microenvironment. We asked how the absence of
NKR-P1B receptor impacts tumour growth through immune suppression by MDSCs in
the tumour microenvironment. We analyzed tumours and spleens from WT and KO
MMTV-PyVT mice, and spleens from non-transgenic mice without tumours. MDSCs are
detected in the spleen and tumours as CD45+CD11b+GR-1+ cells (Figure 6A and C). We
found that there was an increased frequency of MDSCs in the tumours, and to a lesser
extent in the spleens, from KO mice compared with WT mice. Fewer MDSCs are
detectable in spleens of non-transgenic mice (Figures 6B and D). When we compared
MDSC infiltration into tumours of different stages of progression, we observed that latestage tumours (>1cm) have a higher proportion of tumour-infiltrating MDSCs in tumours
from both the WT and KO mice compared with earlier stage tumours (<0.5-1cm) (Figure
6B and D).
MDSCs express Clr-b, the ligand for NKR-P1B receptor (Figure 6E). We compared
the mean fluorescence intensity (MFI) of Clr-b staining in MDSCs from tumours and
spleens in the WT and KO MMTV-PyVT mice and found that Clr-b expression is
reduced in tumour-infiltrating MDSCs in the large tumours from KO mice compared to
the WT mice but not in the spleens (Figure 6F and G). These data indicate that increase
numbers of MDSCs in the mammary tumours from KO mice could exert greater immune
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suppressive activity on NK cells compared to the tumours in WT mice. The data also
suggest a possible involvement of NKR-P1B:Clr-b interactions in the suppression of NK
cell activity by MDSCs.
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Figure 9: MDSC infiltration into tumours of MMTV-PyVT mice.
A, comparison of proportion of tumour-infiltrating MDSCs in WT and Nkrp1b-/MMTV-PyVT tumours. Gating on MDSC population, defined as GR-1+CD11b+ cells. B,
graphical representation of frequencies of MDSCs (GR-1+CD11b+) in WT and KO
tumours >1cm (L), 0.5-1cm (M), <0.5 cm(S). WT tumours: L, n=8; M, n=5; S, n=7.
NKR-P1B-KO tumours: L, n=10; M, n=11; S, n=12. C, comparison of proportion of
MDSCs in spleen of non-transgenic mice, and WT and NKR-P1B-KO MMTV-PyVT
mice. D, graphical representation of the frequencies of MDSCs in spleens (GR1+CD11b+) of non-transgenic mice, and in WT and NKR-P1B-KO MMTV-PyVT mice.
WT, n=8; KO, n=12; non-transgenic, n=8. WT vs non-transgenic, P <0.05. KO vs nontransgenic, P<0.01. E, histogram plot of Clr-b expression on tumour-infiltrating MDSCs.
MDSCs in tumours from NKR-P1B-deficient and WT MMTV-PyVT mice express Clr-b
as indicated by the solid line (Nkrp1b-/-) and the shaded area (WT). Staining with the
secondary antibody alone was used to assess non-specific background staining (dotted
line). F, graphical representation of mean fluorescence intensity (MFI) of Clr-b expressed
on MDSCs in WT and KO tumours >1cm (L) and <0.5 cm(S). WT tumours: L, n=7; M,
n=2; S, n=3. NKR-P1B-KO tumours: L, n=7; M, n=7; S, n=8. MFI is normalized to
isotype control. G, graphical representation of mean fluorescence intensity of Clr-b
expressed on MDSCs in non-transgenic mice, WT and NKR-P1B-KO MMTV-PyVT
mice. Spleen MDSCs: WT, n=6; KO, n=11; non-transgenic, n=4.
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7. Clr-b is involved in mammary tumorigenesis induced by E0771 mammary
adenocarcinoma cells.
The MMTV-PyVT mammary tumour model demonstrated a role of NKR-P1B:Clr-b
recognition axis in NK cell-mediated immune responses against Clr-b- mammary
tumours. We used a second model of mammary tumours in mice induced by injection of
E0771 mammary adenocarcinoma cells into the mammary fatpad to confirm our results
obtained in the MMTV-PyVT mouse model. E0771 cells express Clr-b. We confirmed
the expression of Clr-b in E0771 cells using flow cytometry staining with an anti-Clr-b
(clone 4A6) antibody followed by anti-rat IgM-PE secondary antibody (Figure 7B). To
further address a direct role of Clr-b in tumour cells, we used the CRISPR-Cas9 editing
system to disrupt the Clr-b gene in E0771 cells and generated the E0771-Clr-b-/- cell line
(Figure 7A). The CRISPR-mediated knockout of Clr-b in E0771 cells yielded at least 2
clones with different mutations. Mutation 1 is an insertion of a cytosine residue at
position 40 relative to the ATG start codon. The new stop codon (TAA) was created at
position 73-75 in-frame with the ATG start codon. This mutation resulted in a 23 amino
acid truncated protein. Mutation 2 is a deletion of 2 cytosine residues at position 37 and
38 relative to the ATG start codon. The new stop codon (TAA) was created at position 71
to 73 in-frame with the ATG start codon. We confirmed the absence of Clr-b expression
in the edited E0771-Clr-b-/- cells using the same anti-Clr-b antibody (Figure 7A).
In preliminary experiments to determine if Clr-b on E0771 cells play a role in
tumorigenesis and anti-tumour immune responses, the E0771 and E0771-Clr-b-/- cells
were injected into the mammary fat pad of WT mice. Tumour growth was found to be
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slower in mice that received E0771-Clr-b-/- cells compared to those injected with E0771
cells (Figure 7B). This suggests that Clr-b is involved in mammary tumorigenesis,
possible through the inhibition of NK cell responses via the NKR-P1B receptor against
implanted tumour cells. Further experiments with larger groups of mice are needed to
determine the statistical significance of these observations and the role of NKR-P1B:Clrb interaction on anti-tumour immune responses in this model of mammary tumorigenesis.
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Figure 10: Knockout of Clr-b mediated by CRISPR-Cas9 editing system.
A, a representation of exon 1 cDNA (blue box) of the Clec2d gene and a portion of exon
2 cDNA (yellow box) of the Clec2d gene where the early stop codon was produced by
the frameshift mutation in both clones. The sequence of the gRNA (5’
CTACCTATGCTTAGTCCCAC 3’) is highlighted in yellow. Wild type exon 1 Clr-b
sequence is shown as a reference. Mutation 1 and 2 are both depicted as an insertion of a
cytosine residue (highlighted in blue) and deletion of 2 cytosine residues (highlighted in
pink). Early stop codons introduced in exon 2 of the cDNA are highlighted in red. B,
E0771 (mouse mammary adenocarcinoma) cells express Clr-b (ligand for NKR-P1B
receptor) indicated by a shift in the fluorescence intensity of cells stained with anti-Clr-b
and a fluorescently labeled secondary anti-rat IgM antibody (solid line). Staining with the
secondary antibody alone was used to assess non-specific background staining (shaded)
(left histogram). Clr-b expression was knocked out in E0771 cells using CRISPR-Cas9.
One representative Clr-b knockout clone of E0771 cell is shown. Clr-b expression knock
out was reveal by the lack of staining with anti-Clr-b and a fluorescently labeled
secondary anti-rat IgM antibody (solid line) compared to the secondary antibody alone
(shaded) (right histogram). C, tumours detected at the site of WT E0771(black lines, n=4)
or Clr-b-/- E0771 (red lines, n=4) cells into WT female mice. Each line represents a single
tumour in a single mouse.
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CHAPTER 4: DISCUSSION
NK cells can infiltrate solid tumours to execute their effector functions and
suppress tumour growth. Phenotypic changes to immune cells in the tumour
microenvironment have already been identified in breast cancer patients, such as the
decrease in peripheral blood lymphocytes and impairment of IFN-γ

209

. In addition,

tumour immunoediting occurs in the tumour microenvironment which is implicated in
progression of the disease

210

. In this study, we use the MMV-PyVT transgenic model of

spontaneous tumour development to determine the role of NKR-P1B:Clr-b recognition
in mammary tumour immunosurveillance. NK cells and ILC1-like cells in the MMVPyVT mouse model of breast cancer participate in cancer immunosurveillance

41,211

. The

inhibitory receptor, NKR-P1B, and its cognate ligand, Clr-b, regulate innate immune
responses against cancer and the receptor is required for missing-self recognition of cells
which lack Clr-b 46. m 46. Tu et al. have shown in the MMTV-PyVT mammary tumour
model that Ly49 inhibitory receptor-deficient mice were less able to control tumour
growth 41. They also showed tumour immunoediting since tumours from Ly49-deficient
mice have lower expression of H-2Kb, the ligand for Ly49 receptors, in end-stage
tumours

41

. In our study, we show that mammary tumours from MMTV-PyVT+ mice

with intact NKR-P1B receptor function remain tumour-free longer than NKR-P1Bdeficient mice (Figure 1B). Mammary tumours of MMV-PyVT mice lack the expression
of Clr-b, the ligand for NKR-P1B. In the WT mice, NKR-P1B receptor would engage the
NK cell missing-self response against the MMTV-PyVT tumours resulting in delayed
tumour appearance. When the receptor is absent, as in the NKR-P1B-deficient mice, the
missing-self response is defective and the NK cells cannot sense the absence of Clr-b,
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which results in a lack of NK effector response against tumour cells and earlier tumour
development.
A second mammary tumour model was also used in this study to understand how
Clr-b expression in mammary tumours affects NKR-P1B immunosurveillance. This
breast cancer model is the induction of mammary tumours through the injection of E0771
cells into mammary fat pads of syngenic mice, namely B6 mice. We injected WT and
CRISPR-mediated Clr-b-deficient E0771 cells into WT mice and our preliminary data
shows that tumours induced by the injection of Clr-b KO E0771 cells develop less rapidly
than those induced by the injection of Clr-b WT E0771 cells. The absence of Clr-b
detected by NKR-P1B receptor cause NK cells to deploy the missing-self response and
destroy the target cell, thereby, slowing the progression of Clr-b-deficient E0771 cell
compared to the E0771 cells with intact Clr-b expression. A study by Tu et al. revealed
that E0771 cells deficient of MHC-I molecules (H-2Kb- and H-2Db) were more
susceptible to killing by NK cells via missing-self recognition by the inhibitory Ly49
receptors 41. In vivo, they showed that tumours induced by MHC-I-deficient E0771 cells
grew less rapidly in Ly49 WT mice

41

. They also showed that mice lacking Ly49

expression developed tumours more rapidly and the tumours grew larger and faster than
Ly49 WT mice41. It remains to be seen if our NKR-P1B-deficient mice will show
impaired missing-self response against Clr-b-deficient E0771 cells and increased
mammary tumour susceptibility. Injection of Clr-b WT and KO E0771 cells into WT and
NKR-P1B-KO NK cells will further reveal the role of the NKR-P1B:Clr-b axis in NK
cell immunosurveillance of mammary tumours. Since inhibitory receptors are required
for the education of NK cells, the expression of NKR-P1B and other inhibitory receptors
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dictates the responsiveness of NK cells toward stimulation

212

. We expect to see

decreased target cell lysis when NK cells lack NKR-P1B and E0771 cells lack Clr-b since
there would be a loss of Clr-b-dependent missing-self recognition. Furthermore, it is
important to consider alternative NK cell receptors recognizing Clr-b or NKR-P1B
recognizing other Clr family members. For example, we know that NKR-P1G recognizes
Clr-d, -f, and -g and NKR-P1F recognizes Clr-c, -d, and -g . Therefore, there may be
other interactions between Clr-b and NKR-P1 family members or NKR-P1B and Clr
family members which are yet to be discovered.
Tumour cells can evade immune recognition through phenotypic changes such as
over- or under-expressing MHC-I to evade detection by NK cells or CD8+ T cells,
respectively. Alternatively, tumors cells may produce factors within the tumour
microenvironment which disarm immune cells. Gao et al. found that NK cells (CD49aCD49b+EOMES+) may be converted into less mature intermediate type 1 innate
lymphoid (intILC1, CD49a+CD49b-EOMES+) populations and ILC1 (CD49a+, CD49b-,
EOMESint) populations through TGF-β-driven conversion

213

. They found that intILC1s

and ILC1s favoured tumour growth and metastasis, unlike mature tumour-infiltrating NK
cells

213

. Another group isolated NK cells from MMTV-PyVT mice and found that they

were CD27loCD11blo and expressed low levels of DX5 (CD49b), similar to our own
findings, which is indicative of an immature NK cell phenotype

214

. Additionally, NK

cells in the tumour microenvironment have an uneducated phenotype

215

. Other studies

have shown NK cell exhaustion in the tumour microenvironment results in
downregulation of EOMES174. We have observed loss of EOMES expression and
downregulation of CD49b in mammary tumour-infiltrating NK cells. It has yet to be

69

determined whether we are seeing an immature NK cell phenotype, conversion of NK
cells to ILC1-like cells, or NK cell exhaustion. Our results indicate that NK cells
(EOMES+Tbet+) and ILC1/NK cells (EOMES-Tbet+) both express NKR-P1B. We also
found that in the NKR-P1B KO tumours there’s a higher proportion of EOMES-CD49a+
ILC1/NK cells compared with EOMES+CD49b+ (Figures 2B, 2C, 3B, 3F). There are
significantly more EOMES+ NK cells in the end-stage tumours of WT mice. We may be
seeing conversion of NK cells into immature ILC1-like cells driven be the tumour
microenvironment, which is enhanced in the absence of the NKR-P1B receptor. We do
not see such a difference in the spleens of the same WT and KO tumour-bearing mice,
which may point to a factor in the tumour microenvironment which could be favoring this
conversion. Additionally, there is a decrease in granzyme B+ NK cells in the tumours of
NKR-P1B KO mice compared with the WT mice. The reduction in NK cell effector
activity in tumours of KO mice could be due to the loss of EOMES expression but can
also be caused by additional factors in the tumour microenvironment directly suppressing
NK cell activity.
MDSCs are myeloid cells that expand rapidly during tumour progression and
suppress immune cell activity. MDSCs have been shown to produce high quantities of
TGF-β, which is known to suppress the transcription of perforin and granzymes. We
found that there was an increase in the frequency of tumour-infiltrating MDSCs in NKRP1B KO mice compared with WT mice and the frequency of MDSCs is directly
proportional to tumour progression. NKR-P1B KO tumour are more aggressive, and the
environment better accommodates tumour-infiltrating MDSCs. A study by Li et al.
showed that membrane-bound TGF-β1 on MDSCs suppresses NK cell activity
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216

. It is

possible that TGF-β produced by MDSCs are driving conversion of NK cells to less
mature ILC1s as another mechanism of immune suppression in tumours. In vitro studies
with MDSCs and NK cells may further our understanding of the mechanisms of NK cell
immunosuppression employed by MDSCs. We also observed that MDSCs express Clr-b
and its expression is greater in tumour-infiltrating MDSCs from WT mice compared with
KO mice and it is also proportional to the stage of tumour progression. This may indicate
that MDSC-expressed Clr-b may play a role in immune suppression. One possibility is
that Clr-b-expressing MDSCs are selected in the tumours of WT mice to inhibit NK cell
activity via the NKR-P1B receptor. This may be another mechanism of immune
suppression by MDSCs in mammary tumours of WT mice. In NKR-P1B-KO mice, Clr-b
is downregulated in MDSCs since it will not be required in suppression of NK cell
activity via this receptor. Further studies will address the role of NKR-P1B receptor in
NK cell inhibition by MDSCs and the effect of Clr-b-deficient MDSCs on immune
suppression of NK cells.
It is important to consider NK cell exhaustion when investigating tumourinfiltrating lymphocytes. The tumour microenvironment (TME) is an extremely hostile
environment to tumour-infiltrating immune cells, like NK cells and cytotoxic T
lymphocytes (CTL), since it represses their cytotoxicity through the recruitment of
MDSCs and other immune suppressive cells that contribute to immune cell exhaustion
217

. In 2019, Alvarez et al. have identified a “phenotypic signature of NK cell exhaustion”

by exposing NK cells to sustained IL-15 stimulation. They found that resulting NK cells
were characterized by an upregulation of KLRG1, an inhibitory receptor and terminal
differentiation marker, downregulation of EOMES, and downregulation of NKG2D,
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DNAM1, TRAIL, and FasL,
proliferation marker
breast cancer

218

. These NK cells also had lower levels of Ki67, a

218

. Ligands for KLRG1, E- and N-cadherin, are upregulated in

219

. One study showed that KLRG1-deficient mice had significantly less

lung tissue tumours than their WT counterparts

220

. To better understand what is

happening to NK cells and what the effect of NKR-P1B:Clr-b is in the TME, it would be
beneficial to further study the phenotype of NK cells in our models of breast cancer.
Ultimately the goal of these studies is to be able to understand the mechanisms of
interaction of dynamics of NKR-P1B:Clr-b in the mammary tumour microenvironment in
mice since the mouse NKR-P1B:Clr-b axis is a model for the human NKR-P1A:LLT1
system in cancer. NKR-P1A expression is frequently associated with a favourable
outcome in human malignancies and disruption of NKR-P1A:LLT1 has been shown to
enhance NK cell-mediated lysis of a triple-negative breast cancer cell line

221,222

.

Therefore, a better grasp of the role of these receptors in cancer and NK cell interactions
in the tumour microenvironment will be beneficial with the design of future NK cellbased immunotherapy.
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